[1]
|
Sharma, P., Goswami, S., Raychaudhuri, D., et al. (2023) Immune Checkpoint Therapy—Current Perspectives and Future Directions. Cell, 186, 1652-1669. https://doi.org/10.1016/j.cell.2023.03.006
|
[2]
|
Weiss, S.A. and Kluger, H. (2021) CheckMate-067: Raising the Bar for the Next Decade in Oncology. Journal of Clinical Oncology, 40, 111-113. https://doi.org/10.1200/JCO.21.02549
|
[3]
|
Robert, C., Carlino, M.S., McNeil, C., et al. (2023) Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab versus Ipilimumab in Advanced Melanoma. Journal of Clinical Oncology, 41, 3998-4003. https://doi.org/10.1200/JCO.22.01599
|
[4]
|
Merck公司2023年财报[EB/OL]. https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/, 2024-03-22.
|
[5]
|
Romero, Y., Wise, R. and Zolkiewska, A. (2020) Proteolytic Processing of PD-L1 by ADAM Proteases in Breast Cancer Cells. Cancer Immunology, Immunotherapy, 69, 43-55. https://doi.org/10.1007/s00262-019-02437-2
|
[6]
|
Patsoukis, N., Wang, Q., Strauss, L., et al. (2020) Revisiting the PD-1 Pathway. Science Advances, 6, Article eabd2712. https://doi.org/10.1126/sciadv.abd2712
|
[7]
|
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., et al. (2012) Programmed Cell Death 1 Forms Negative Costimulatory Microclusters that Directly Inhibit T Cell Receptor Signaling by Recruiting Phosphatase SHP2. Journal of Experimental Medicine, 209, 1201-1217. https://doi.org/10.1084/jem.20112741
|
[8]
|
Chen, Y., Liu, P., Gao, F., et al. (2010) A Dimeric Structure of PD-L1: Functional Units or Evolutionary Relics? Protein & Cell, 1, 153-160. https://doi.org/10.1007/s13238-010-0022-1
|
[9]
|
Hira-Miyazawa, M., Nakamura, H., Hirai, M., et al. (2018) Regulation of Programmed-Death Ligand in the Human Head and Neck Squamous Cell Carcinoma Microenvironment Is Mediated through Matrix Metalloproteinase-Mediated Proteolytic Cleavage. International Journal of Oncology, 52, 379-388. https://doi.org/10.3892/ijo.2017.4221
|
[10]
|
Kathleen, M.M., Petra, R.-M., Long, Y., et al. (2022) Soluble PD-L1 as an Early Marker of Progressive Disease on Nivolumab. Journal for ImmunoTherapy of Cancer, 10, Article e003527. https://doi.org/10.1136/jitc-2021-003527
|
[11]
|
Yin, Z., Yu, M., Ma, T., et al. (2021) Mechanisms Underlying Low-Clinical Responses to PD-1/PD-L1 Blocking Antibodies in Immunotherapy of Cancer: A Key Role of Exosomal PD-L1. Journal for ImmunoTherapy of Cancer, 9, Article e001698. https://doi.org/10.1136/jitc-2020-001698
|
[12]
|
Nagato, T., Ohkuri, T., Ohara, K., et al. (2017) Programmed Death-Ligand 1 and Its Soluble Form Are Highly Expressed in Nasal Natural Killer/T-Cell Lymphoma: A Potential Rationale for Immunotherapy. Cancer Immunology, Immunotherapy, 66, 877-890. https://doi.org/10.1007/s00262-017-1987-x
|
[13]
|
Bardhan, K., Aksoylar, H.-I., Le Bourgeois, T., et al. (2020) Publisher Correction: Phosphorylation of PD-1-Y248 Is a Marker of PD-1-Mediated Inhibitory Function in Human T Cells. Scientific Reports, 10, Article No. 15905. https://doi.org/10.1038/s41598-020-71090-y
|
[14]
|
Saunders, P.A., Hendrycks, V.R., Lidinsky, W.A., et al. (2005) PD-L2: PD-1 Involvement in T Cell Proliferation, Cytokine Production, and Integrin-Mediated Adhesion. European Journal of Immunology, 35, 3561-3569. https://doi.org/10.1002/eji.200526347
|
[15]
|
Jiang, M., Liu, M., Liu, G., et al. (2023) Advances in the Structural Characterization of Complexes of Therapeutic Antibodies with PD-1 or PD-L1. mAbs, 15, Article 2236740. https://doi.org/10.1080/19420862.2023.2236740
|
[16]
|
Zak, K.M., Grudnik, P., Guzik, K., et al. (2016) Structural Basis for Small Molecule Targeting of the Programmed Death Ligand 1 (PD-L1). Oncotarget, 7, 30323-30335. https://doi.org/10.18632/oncotarget.8730
|
[17]
|
Guo, J., Yu, F., Zhang, K., et al. (2024) Beyond Inhibition against the PD-1/PD-L1 Pathway: Development of PD-L1 Inhibitors Targeting Internalization and Degradation of PD-L1. RSC Medicinal Chemistry. https://doi.org/10.1039/D3MD00636K
|
[18]
|
Muszak, D., Surmiak, E., Plewka, J., et al. (2021) Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein—Protein Interaction. Journal of Medicinal Chemistry, 64, 11614-11636. https://doi.org/10.1021/acs.jmedchem.1c00957
|
[19]
|
Zheng, X. and Chupak, L.S. (2015) Compounds Useful as Immunomodulators. WO Patent No. 2015034820A1.
|
[20]
|
Ding, M., Hewawasam, P., Langley, D.R., et al. (2015) Compounds Useful as Immunomodulators. WO Patent No. 2015160641A2.
|
[21]
|
Hewawasam, P., Langley, D.R., Yeung, K.-S., et al. (2017) Compounds Useful as Immunomodulators. WO Patent No. 2017066227A1.
|
[22]
|
Wu, L.X., Li, J.W., Qi, C., et al. (2018) Benzooxazole Derivatives as Immunomodulators. WO Patent No. 2018-119266A1.
|
[23]
|
冯志强, 陈晓光, 杨阳, 等. 烟醇醚类衍生物、及其制法和药物组合物与用途[P]. 中国专利, 114853634A. 2022-08-05.
|
[24]
|
Cho, A., Graupe, M., Xu, J., et al. (2019) Pd-1/Pd-L1 Inhibitors. WO Patent No. 2018195321A1.
|
[25]
|
王玉光, 张农, 吴添智, 等. 芳香乙烯或芳香乙基类衍生物、其制备方法、中间体、药物组合物及应用[P]. 中国专利, 109988144A. 2019-07-09.
|
[26]
|
Sarina, P.-P., Tara, M., Solmaz, S., et al. (2020) 419 Pharmacodynamic Biomarkers Demonstrate T-Cell Activation in Patients Treated with the Oral PD-L1 Inhibitor INCB086550 in a Phase 1 Clinical Trial. Journal for ImmunoTherapy of Cancer, 8, A255.
|
[27]
|
Eric Van, C., Hans, P., Brant, D., et al. (2021) 529 Phase 1 Study of INCB086550, an Oral PD-L1 Inhibitor, in Immune-Checkpoint Naive Patients with Advanced Solid Tumors. Journal for ImmunoTherapy of Cancer, 9, A559. https://doi.org/10.1136/jitc-2021-SITC2021.529
|
[28]
|
Pinato, D.J., Banerji, U., Rottey, S., et al. (2023) 134P A Phase I Study Exploring the Safety and Tolerability of the All Molecule PD-L1 Inhibitor INCB099318 in Select Advanced Solid Tumors. Immuno-Oncology Technology, 20, Article 100606. https://doi.org/10.1016/j.iotech.2023.100606
|
[29]
|
美国临床试验数据库[EB/OL]. https://clinicaltrials.gov/, 2024-02-24.
|
[30]
|
Hans, P., Thierry, L., Marie, R., et al. (2022) 734 A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor, INCB099280, in Patients with Select Advanced Solid Tumors. Journal for ImmunoTherapy of Cancer, 10, A766.
|
[31]
|
David, P., Ruth, P., Martin, G., et al. (2022) 622 A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor, INCB099318, in Patients with Select Advanced Solid Tumors. Journal for ImmunoTherapy of Cancer, 10, A654.
|
[32]
|
Lai, F., Ji, M., Huang, L., et al. (2022) YPD-30, a Prodrug of YPD-29B, Is an Oral Small-Molecule Inhibitor Targeting PD-L1 for the Treatment of Human Cancer. Acta Pharmaceutica Sinica B, 12, 2845-2858. https://doi.org/10.1016/j.apsb.2022.02.031
|
[33]
|
Jiang, J., Zou, X., Liu, Y., et al. (2021) Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies. Frontiers in Pharmacology, 12, Article 677120. https://doi.org/10.3389/fphar.2021.677120
|
[34]
|
Wang, Y., Liu, X., Zou, X., et al. (2021) Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug. Pharmaceutics, 13, Article 598. https://doi.org/10.3390/pharmaceutics13050598
|
[35]
|
再极医药[EB/OL]. http://www.maxinovel.com/news.html, 2024-02-24.
|
[36]
|
贝达药业[EB/OL]. https://www.bettapharma.com/newdrug/projects, 2024-03-16.
|
[37]
|
王义乾, 张垚, 张春辉, 等. 免疫调节剂及其组合物和应用[P]. 中国专利, 115884972A. 2023-03-31.
|
[38]
|
阿诺生物医药[EB/OL]. https://cn.adlainortye.com/index.php/newsinfo?id=81, 2024-03-15.
|
[39]
|
Yu, Z.Y., Li, P., Xu, B.D., et al. (2021) PD-1/PD-L1 Inhibitors. WO Patent No. 2021129584A1.
|
[40]
|
Liu, L., Yao, Z., Wang, S., et al. (2021) Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[c][1,2,5] Oxadiazole Derivatives as Potent PD-L1 Inhibitors with in vivo Antitumor Activity. Journal of Medicinal Chemistry, 64, 8391-8409. https://doi.org/10.1021/acs.jmedchem.1c00392
|
[41]
|
Wang, T., Cai, S., Wang, M., et al. (2021) Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. Journal of Medicinal Chemistry, 64, 7390-7403. https://doi.org/10.1021/acs.jmedchem.1c00010
|
[42]
|
孙宏斌, 刘鎏, 王仕军, 等. 联苯类化合物及其制备方法和医药用途[P]. 中国专利, 111909108A. 2020-11-10.
|
[43]
|
蒋晟, 郝海平, 王天雨, 等. 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物[P]. 中国专利, 111718310A. 2020-09-29.
|
[44]
|
徐云根, 张宏波, 朱启华, 等. 一种新型联苯类衍生物及其制备方法与医药用途[P]. 中国专利, 113135895A. 2021-07-20.
|
[45]
|
徐云根, 张宏波, 朱启华, 等. 一种新型联苯类衍生物及其制备方法与医药用途[P]. 中国专利, 113461668A. 2021-10-01.
|
[46]
|
Guo, Y., Jin, Y., Wang, B., et al. (2021) Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/ PD-L1 Pathway through PD-L1 Dimerization. International Journal of Molecular Sciences, 22, Article 4766. https://doi.org/10.3390/ijms22094766
|